Ganges, France

Stephane Cociancich

This inventor holds 1 USPTO granted patent, plus 1 CIPO patent. Top assignee: Technische Unversität Berlin. Active years: 2019.


% Patents Active = 100.0


Average Co-Inventor Count = 10.0

ph-index = 1


Company Filing History:


Years Active: 2019

Loading Chart...
Loading Chart...
1 patent (USPTO):Explore Patents

Title: Innovations of Stephane Cociancich

Introduction

Stephane Cociancich is a notable inventor based in Ganges, France. He has made significant contributions to the field of antibiotic compounds, particularly through his innovative research and patenting activities. His work focuses on developing new methods for treating bacterial infections, which is crucial in today's medical landscape.

Latest Patents

Cociancich holds a patent for "Albicidin derivatives, their use and synthesis." This patent describes antibiotic compounds characterized by a general formula that includes various building blocks and linkers. The compounds are designed for use in treating diseases, specifically bacterial infections. This innovation highlights the potential for new therapeutic approaches in combating antibiotic resistance.

Career Highlights

Cociancich is affiliated with Technische Universität Berlin, where he engages in research that bridges the gap between academia and practical applications in medicine. His work has garnered attention for its relevance and potential impact on public health.

Collaborations

Throughout his career, Cociancich has collaborated with esteemed colleagues, including Roderich Suessmuth and Alexander Pesic. These partnerships have enriched his research and contributed to the advancement of antibiotic development.

Conclusion

Stephane Cociancich's contributions to antibiotic research and his innovative patent demonstrate his commitment to improving medical treatments. His work is a testament to the importance of innovation in addressing global health challenges.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to [email protected]
Loading…